Other OTC - Delayed Quote • USD Grifols, S.A. (GIFOF) Follow 6.87 0.00 (0.00%) As of April 5 at 10:43 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for GIFOF 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: GIFOF View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Grifols 2023 Annual Report on Form 20-F filed with the SEC Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper Grifols Plans First Bond Sale Since Short Seller Attack Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening Health Care Roundup: Market Talk UPDATE 2-Europe's STOXX 600 logs weekly gains, US jobs data in focus Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct GRFS or ZTS: Which Is the Better Value Stock Right Now? Grifols announces positive topline phase 3 fibrinogen clinical trial results Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now UPDATE 1-Spain's Grifols sues Gotham City fund, JV over damaging report
